Abstract: A dosage form contains a polymeric matrix, containing one or more polymer(s) and a biologically active ingredient. The polymeric matrix contains 10% by weight or more of the one or more polymer(s). The one or more polymer(s) are polymerized from a monomer mixture containing the monomers (a) 70 to 95% by weight of 2-ethylhexyl methacrylate (EHMA) and ethyl methacrylate (EMA), or 2-ethylhexyl methacrylate (EHMA) and methyl methacrylate (MMA); (b) 0 to 25% by weight of a C2 to C6 hydroxy-alkylester of acrylic acid or methacrylic acid; and (c) 2.5 to 20% by weight of a C2 to C8 alkyl ester of acrylic acid or of methacrylic acid with a quaternary cationic group in the alkyl group.

Abstract: An oral delivery system based on in situ forming protein/polysaccharide coacervates is described herein. The system comprises an active ingredient dispersed in a dry, homogenous powder mixture of a protein powder and a polysaccharide powder, which is able to form a protein/polysaccharides complex coacervate in situ upon immersion in gastric fluid, thereby conferring gastric protection and/or modified-release to the active ingredient. Varying the ratio of protein powder to polysaccharide powder in the oral delivery system varies the level of gastric protection and/or rate of release to the active ingredient. The ability of the system described herein to be based on natural and/or naturally-derived biopolymers provides commercial advantages in terms of regulatory approval and/or growing consumer demand for such products.

Abstract: The present invention relates to an enteric coating tablet comprising: a core containing, as an active ingredient, dimethyl fumarate or a pharmaceutically acceptable salt thereof; and an enteric coating layer, and provides a tablet, which exhibits an effect equal to that of a capsule dosage form currently on the market, can be prepared through a simple preparation process, and is a dosage form having excellent storage stability and administration convenience, and thus can be applied to various patient groups.

Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.

Abstract: The invention describes a core shell microcapsule wherein the capsule shell is an interfacial copolymer formed of a modified polysaccharide free radical cross-linked with a multifunctional (meth)acrylate. The polysaccharide is hydrophobically modified with an adduct containing at least one unsaturated bond. The modification imparts hydrophobic character to the polysaccharide to act as an emulsifier, driving the modified polysaccharide to an oil-water interface of an encapsulation emulsion described, and creates an active bonding site for free-radical polymerization between the polysaccharide and multifunctional (meth)acrylate, thereby forming a microcapsule shell surrounding the core material.

Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone. Also provided are nanoformulations based on nanoparticles comprising one or more anti-cancer agents and/or one or more modulators for preventing and/or treating neoplasms.

Abstract: Provided are a surface-aminated mesoporous silica nanoparticle, a method of preparing the same, use of the nanoparticle for delivering a ribonucleoprotein, and use of the nanoparticle for the prevention or treatment of cancer. The surface-aminated mesoporous silica nanoparticle may be loaded with large RNPs such as Cas9-RNP, and thus may be applied to treatment of various diseases treatable by gene editing.

Abstract: A portable surface acoustic wave (SAW)-generating system, a transdermal patch, and methods of treatment with improved transdermal administration of drugs are provided. Application of the transdermal patch comprising a therapeutically effective amount of the cannabis id, such as a cannabis drug, to the skin in combination with SAW results in a synergistic effect on delivery and absorption of the at least one drug as compared to topical administration of the drug via the transdermal patch without the surface acoustic waves generated by the portable SAW-generating system.

Abstract: The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

Abstract: Disclosed are methods of modulating macrophage activation to treat various diseases, such as cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases. Also disclosed are methods of identifying compounds useful for modulating macrophage activation as means to treat cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention is directed to Anti-Apicomplexan compositions, methods for producing the same, and methods for their use.

Abstract: The present invention is directed to a composition comprising a combination of thymoquinone (TQ) and one or more additional biologically active agents, wherein said biologically active agents are selected from the group consisting of carotenoids, Cannabis-related compounds and pycnogenol. In one preferred embodiment, the TQ is contained in cold-pressed Nigella sativa oil, wherein said oil is characterized by a TQ concentration of at least 1.5% (w/w) and a free fatty acid (FFA) content of 3.5% (w/w) or less. The present invention is also directed to methods for treating or preventing inflammatory conditions by means of administering these compositions.

Abstract: The invention relates to compounds, compositions, and methods for the treatment of lupus. The compounds of the present invention are isoLG savaging compounds.

Abstract: Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.

Abstract: Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.

Abstract: Provided herein are methods of treating a nerve injury in a subject in need thereof and methods of treating an injured neuron using diaryl hydrazones.

Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation. The combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and 5-ASA agent and use of such combination. A kit-of-parts and a pharmaceutical composition comprising such a combination.

Abstract: There is disclosed an oral pharmaceutical composition for the treatment of multiple diseases comprising a denatonium cation salt and a sour anion selected from the group consisting of acetate (DA), citrate (DC) tartrate (CT), maleate (DM) and combinations thereof (collectively “denatonium salt”) and pharmaceutical excipients for gastric release of the denatonium salt. There is further disclosed an oral immediate release pharmaceutical composition to substantially release an API (active pharmaceutical ingredient) in the gastric area of the GI tract formulation, wherein the API comprises an effective amount of the denatonium salt. Preferably, the oral immediate release pharmaceutical formulation comprises from about 0.5 g to about 5 g of the denatonium salt delivering a daily dose of the denatonium salt from about 20 mg to about 150 mg to a human adult.

Abstract: The present disclosure provides a method of treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305, wherein the therapeutically effective amount of the compound increases a blood calcium concentration (cCa) to a range of about 7.5 mg/dL to about 10.5 mg/dL, such as about 8.5 mg/dL to about 10.5 mg/dL. Also provided herein is a dosing finding method for treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I) or CLTX-305 according to one or more dosing regimens.

Abstract: The disclosure relates to methods of preventing or treating age-related diseases or conditions in a subject. The method comprises targeting the kynurenine pathway.

Abstract: In some aspects, provided herein are antimicrobial compositions comprising partially esterified polygalacturonic acid and certain fatty acids (e.g., caprylic acid). In some embodiments, the antimicrobial composition may be administered (e.g., topically or orally) to a subject, such as a human patient to treat an infection (e.g., an infection comprising a biofilm). In some aspects, improved catheters are provided.

Abstract: Interpretation: This is the first ever report to uncover a tangible lipidomic basis by which maternal emotional well-being may influence fetal neurodevelopment and the later risk for psychopathology. This novel insight points to the potential utility of nutritional approaches among pregnant women with high levels of depressive symptoms in the prevention of offspring risk for later socio-emotional behavioral problems predictive of future psychopathology. Such a novel approach is particularly pertinent in light of the preference to avoid pharmacological interventions such as anti-depressant medications during pregnancy.

Abstract: The present invention relates to compositions comprising one or more extracts and/or compounds having retinol-like activity and properties and methods of using the compositions to treat the eye.

Abstract: The present invention includes a co-crystal of creatine and citric acid obtained by milling, methods of making the same that include a process for the preparation of co-amorphous formulation of creatine and citric acid, the process comprising: mixing creatine and citric acid; milling the creatine and citric acid for a time sufficient to form a co-amorphous solid, which co-amorphous solid can be converted into a co-crystal, and nutritional supplements that include the same.

Abstract: Provided herein is the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.

Abstract: A skin care composition for promoting the skin microbiome. The composition is formulated for topical application to the skin and comprises (a) lactic acid, lactate or a mixture thereof; (b) urea; and (c) caprylic/capric triglycerides.

Abstract: The present invention is directed to a method for treating Asthma. The method comprises administering to a subject in need thereof 3-methanesulfonylpropionitrile (dapansutrile), or a pharmaceutically acceptable solvate thereof, in an effective amount. The preferred route of administration is oral administration or local administration.

Abstract: Methods for treating or preventing a cognitive impairment in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of an agent that enhances the NO-cGMP-PKG pathway are disclosed.

Abstract: Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.

Abstract: A cannabinoid composition including a cannabinoid oil, such as THC oil or CBD oil, one or more thickeners such as gums, and a compound that forms an inclusion complex with the cannabinoid oil. The composition may include water, and in intermediate stages can include an alcohol. The composition can also include a sweetener to make it a sugar or a syrup. In some embodiments there are no other oils in the composition.

Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.

Abstract: Disclosed herein is a method against coronavirus infection, which includes administering to a subject in need thereof an effective amount of 8-benzoyl-4-methyl-9-phenyl-furo[2,3-h]chromen-2-one or a pharmaceutically acceptable salt thereof.

Abstract: A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating trigeminal neuralgia, the pharmaceutical composition comprising: a carbamate compound of chemical formula 1 or a pharmaceutically acceptable salt thereof, a solvate or a hydrate; and a pharmaceutically acceptable carrier. The pharmaceutical composition, according to the present invention, may enable the efficient prevention or treatment of trigeminal neuralgia.

Abstract: The invention provides methods for treating, suppressing, or preventing detrimental cytokine and/or lipid mediator surges that can result from a variety of different diseases, conditions, and therapeutic treatments, e.g., by inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH).

Abstract: Method of treating or preventing trichomoniasis or T. vaginalis infection in a subject in need thereof, the method involving administering to the subject a therapeutically effective amount of secnidazole or a pharmaceutically acceptable salt in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules. The subject can also have bacterial vaginosis, is HIV-positive, and/or is suffering with metronidazole-resistant trichomoniasis and/or tinidazole-resistant trichomoniasis. The subject can also be a sexual partner of a person with trichomoniasis. The microgranule formulation can also be administered with paromomycin, tinidazole, metronidazole, boric acid or a combination thereof. Pharmaceutical compositions and uses for treating or preventing trichomoniasis or T. vaginalis infection in a subject in need thereof are also contemplated herein.

Abstract: Compositions and methods are described herein that include imidazole compounds that are useful for treatment of certain cancers, particularly metastatic cancers such as of glioblastomas, osteosarcomas, histiocytic sarcomas, mastocytomas, and sarcomas.

Abstract: The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRP? and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface.

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

Abstract: The present disclosure belongs to the technical field of tissue regeneration, and specifically relates to use of tacrolimus in preparation of a medicament for initiating a tissue regeneration function. In the present disclosure, adding the tacrolimus may initiate the tissue regeneration of a non-regenerative distal caudal fin in a caudal fin resection experiment of a zebrafish. The present disclosure finds that tacrolimus inhibits the calcineurin activity and has a novel use for initiating the tissue regeneration of non-regenerative tissues. The present disclosure expands the use field of tacrolimus and has important value.

Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method for treating or preventing an inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.

Abstract: Tacrolimus is an immunosuppressant drug. The present disclosure provides an anti-fibrotic agent by transforming Tacrolimus, such that the anti-fibrotic agent is used for treating fibrosis. The anti-fibrotic agent is not immunosuppressant. In one embodiment, the present invention provides a method to transform Tacrolimus into an anti-fibrotic agent.

Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.

Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Abstract: Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond “a”, and subscript n are described herein.